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Abstract
The objectives of this thesis were 1) to assess feasibility and practicality of gait performance
to help differentiate cognitive diagnoses, 2) to assess differences in gait speed and dual-task
gait cost across the cognitive spectrum, and 3) to determine if poor baseline gait performance
is associated with future cognitive decline, all within a clinical setting. Patients at the Aging
Brain and Memory Clinic completed gait assessment, consisting of a usual gait trial and three
dual-task gait trials, in addition to cognitive and clinical assessments. Patients who had two
clinic visits during the study period were also included in a longitudinal analysis. Gait speed
decreased across the cognitive spectrum and was associated with a more severe cognitive
impairment. Dual-task gait performance on the naming animals condition was also associated
with future cognitive decline. This thesis presents an investigation of gait performance in a
clinical setting with a large diverse cohort.

Keywords
Aging, older adults, cognition, dual-task, gait testing, gait velocity, gait speed

ii

Summary for Lay Audience
This thesis explores the usefulness and feasibility of using a dual-task test, or “walking while
talking” test, to predict which patients in memory clinics are at higher risk of progressing to
dementia. In the past, it has been shown that patients with a more pronounced slowdown
when walking and talking (when compared to just walking) may be more likely to progress
to dementia, but this test has not been thoroughly studied in a clinic setting. We performed
this test on patients who were attending the memory clinic at Parkwood Institute for
evaluation of their memory concerns. We found that this test was feasible to complete, as a
large majority of patients were able to complete the test. We also found that participants with
slow walking speed and those who further slowed down when dual-tasking were more likely
to have been diagnosed with dementia and may be more likely to decline in the following
years. While we would need a larger study with more participants for each diagnosis and a
longer follow-up period to better understand this relationship, these results show that dualtask gait testing in a clinical setting may be useful in better evaluating risk of dementia.
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Key Terms Glossary
Cognition

The set of mental activities carried out by the brain that are involved in
the acquisition, storage, retrieval, and use of information [1].

Mobility

The ability of a person to complete movement in any form, including
walking, completing activities of daily living, exercising, and even
using transportation [2].

Neurodegenerative

Diseases that cause progressive damage to a group of neurons and have

diseases

residual cognitive or motor effects (ex. Alzheimer’s Disease,
Parkinson’s Disease, and amyotrophic lateral sclerosis (ALS)) [3].

SCI

Subjective Cognitive Impairment. A clinical condition characterized by
subjective cognitive complaints but normal scores on tests of cognition
[4].

MCI

Mild Cognitive Impairment. A clinical condition characterized by
subjective cognitive complaints and lower than normal scores on tests
of cognition, but without impairments on activities of daily living and
with absence of dementia [5].

Dementia

A clinical neurocognitive syndrome caused by multiple underlying
diseases which cause chronic decline in cognition [6]. Usually
characterized by objective cognitive impairment which is impacting
activities of daily living [7,8]. The most common cause is thought to be
Alzheimer’s disease.

Gait

The pattern of movement of the human body during locomotion [9].
Mainly used to describe walking [10].

Dual-task gait

Walking while performing a cognitively demanding task.

Dual-task gait speed

The amount of slowdown in gait speed due to the added cognitive task,

cost

expressed as a percent of usual gait speed.

xiii
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Chapter 1

1

Literature Review

As the current population is aging, with this comes cognitive impairments and disability,
of which the most extreme expression is dementia syndromes. Although cognitive
impairment is not the norm in aging, it is very prevalent among older adults [5].
Worldwide, approximately 50 million people are living with dementia, with almost 10
million new cases each year [11]. There are currently over half a million Canadians living
with dementia, and this number is expected to grow by 66% in the next ten years [12].
However, when an older adult has cognitive complaints, it is difficult to discern in the
early stages if they are due to the aging process or to dementia syndromes. In the search
for good biomarkers to detect dementia, those that are easy to perform and clinically
available will be of extreme importance. In this regard, motor biomarkers and physical
performance abilities, including gait performance, are emerging as candidates to detect
those at higher risk of dementia [13]. Recently, it has been postulated that gait
performance while executing a cognitively demanding task can detect those older adults
with subtle brain damage and who are more likely to progress to dementia. Therefore,
this thesis aims to study the association between gait performance, specifically dual-task
gait testing, and cognitive outcomes for older adults at risk of dementia in a clinical
setting, with the goal of establishing feasibility of this testing in real clinical scenarios
and confirm potential predictive abilities. Chapter 1 will provide an overview of
cognitive impairments, gait testing, and the dual-task paradigm. This chapter will discuss
the motor-cognitive interface and how it affects mobility in aging. We conclude by
presenting the study rationale, purpose, and hypotheses.

1.1

Introduction

As research into motor biomarkers of cognition has expanded, dual-task gait testing has
emerged as a “brain stress test” to evaluate the interaction between motor and cognitive
performance [14]. Dual-task gait testing, defined as “walking while performing a
cognitively demanding task”, was found to be associated with future dementia in patients
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with mild cognitive impairment (MCI), a pre-dementia state [15]. As cognitive decline
varies drastically in these prodromal states, both in timing and in magnitude [5], it is
important to determine who is at high risk for dementia as early as possible. Research has
shown that dual-task gait testing may be able to help with this early detection [15],
however this theory has not been thoroughly studied in a memory clinic setting.
Demonstrating feasibility and usefulness in a clinical setting would encourage clinicians
to adopt this testing as part of assessment for memory complaints in older adults. This
thesis will aim to apply previously described dual-task testing methodologies [14] in a
large memory clinic cohort, to determine its feasibility and association with various
cognitive diagnoses.

1.2

Cognition

While there are many definitions of cognition, it is usually conceptualized as “the set of
mental activities involved in the acquisition, storage, retrieval, and use of information”
[1]. Cognition can be broken down into several functions, including memory, speech and
language, and executive functions, such as planning and attention, along with many
others [16]. Several of these cognitive functions will be further explored below as they
relate to Miyake’s models of cognition [17,18]. This model was chosen this model to
follow as it has been applied to dual-task research from its earliest days in cognitive
psychology [19].

1.2.1

Executive Function

Executive function is a higher level cognitive process that produces, regulates, and
monitors goal-directed behaviours [17,20]. Executive function can be further divided into
smaller processes, such as volition, planning, shifting between information sets, multitasking, monitoring and updating working memory, and inhibition [17,20]. Executive
function is commonly linked to the frontal lobe, an anatomical region of the brain which
has an important role in both cognitive and motor networks [17,21]. Patients with damage
to the frontal lobe often show detriments in cognitive processes that are part of executive
function [22]. Earlier research in psychology often referred to executive function tests as
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“frontal tasks” [17]. However, imaging studies have shown that other regions of the
brain, mainly in the parietal lobe, are also activated in tasks of executive function [23].
The frontal lobe is sensitive to age related changes in structural integrity [21,24], which
creates the high prevalence of executive dysfunction in older adults. This is attributed to
the increase in vascular risk factors often seen in older adults, as these can lead to
changes and ultimately damage to white matter in the brain [24]. Decline in executive
function may also precede impairments in memory in both normal aging and in
neurodegenerative diseases [25]. Impairments in executive function are also highly
correlated with falls and slow gait speed in older adults [26]. In a large cohort of older
adults, 35% of patients with low executive function experienced a fall within one year,
compared to only 15% with higher executive function scores [27].

1.2.2

Working Memory

Working memory is a cognitive function that allows the brain to maintain and retrieve
task relevant information [18]. In the past, working memory was often confused with
short term memory. However, there is evidence that the systems function separately, as
those with short term memory impairments are still able to process information to
perform activities of daily living [28]. More recently, working memory has been
associated more with executive function than memory under the model described by
Miyake [17]. While working memory does require some aspects of information storage,
the use of working memory is often more the ability to monitor and update information
during cognitive tasks, which is an important executive function [17]. Working memory
is also associated with walking, as it is required to follow a route or process changing
surroundings [29]. In a study of patients with MCI, poor performance on tests of working
memory was associated with slow usual gait speed and poor performance on dual-task
gait tests [30].

1.2.3

Processing Speed

Processing speed is the speed at which information is processed during higher level
cognitive functions associated with executive function [31]. Processing speed peaks in
adolescence and declines with aging [31]. The processing speed theory of aging
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described by Salthouse [32] proposes that age related decline in cognition can be
attributed to decreased processing speed. Under this theory, slow processing speed causes
decrease in cognitive function in tasks that require time sensitive response and in tasks
that require input from multiple steps to complete later steps of processing. In relation to
mobility, some studies suggest slow walking speed may be due to slowing in processing
speed associated with aging and cognitive decline [33]. An additional study of processing
speed and gait in older adults found that performance on multiple tests of processing
speed explained the association between smaller prefrontal area volume and slow gait
speed [34].

1.2.4

Attention

Attention is described as a number of different processes that are related aspects of how
the brain becomes receptive to stimuli and how it may begin processing these stimuli
[35]. While attention has no one definition, it can be thought of as a subprocess of
executive function [20]. Attention as a process can be separated into focused, sustained,
and divided or alternating attention [20]. Selective attention, or concentration, is the
selection of relevant stimuli and the concurrent suppression of irrelevant stimuli [35].
Sustained attention is the ability to detect stimuli that are unpredictable over a long period
of time [36]. Divided attention is the ability to perform more than one task at once, while
alternating attention is the ability to switch between the two [20,35]. Attentional capacity
varies between individuals and can be affected by many factors, including fatigue, brain
injury, and aging [35]. Divided attention is of particular interest, as it is most sensitive to
changes due to these factors [35] and is representative of the real world condition, as
individuals are often susceptible to multiple attentional demands. Gait as an isolated task
in healthy individuals requires limited attentional resources [37,38]. However, in those
with neurodegenerative or neuromuscular diseases, or when an additional attention
demanding task is added, attention is needed to maintain postural control and maintain
steadiness in walking [37,39].
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1.3

Cognition in Aging

Observed decline in cognition with aging can be attributed to slower processing speed
[32] and depletion of cognitive reserve [40]. Decreased processing speed leads to
cognitive operations not being completed within the required time limit for response. It
can also cause breakdown in simultaneous cognitive operations due to products from
earlier steps being forgotten once later steps are completed [32]. Alternatively, cognitive
reserve is the idea that how different individuals process tasks makes some more resistant
to deficits due to brain pathology [40]. The cognitive reserve theory of decline postulates
that individuals have different levels of processing capacity, but all have a critical
threshold and once one’s capacity declines below this level, clinical and functional
impairments are seen [40]. However, these impairments present differently in different
people, which leads to the differential diagnoses of cognitive impairments seen in clinical
settings.

1.3.1

Spectrum of Cognitive Impairment

There are many diagnoses associated with cognitive impairment that are seen with aging,
but three of these are commonly used in clinical practice. In order of increasing severity,
they are subjective cognitive impairment (SCI), mild cognitive impairment (MCI), and
dementia (see Figure 1.1). SCI, also called subjective cognitive decline (SCD) [4], is
characterized by the presence of memory complaints or worry about decline in cognition
(e.g. slowness and word finding difficulties), with no objective impairment on cognitive
testing (normal for their age and education level). While these patients do not have
objective cognitive impairments, they are still at heightened risk of future cognitive
decline over those without these subjective concerns [41].
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Figure 1.1 Model of the course of cognitive decline in relation to progression of
Alzheimer's Disease pathology. Republished with permission of Annual Reviews,
from Rabin, Smart, & Amariglio (2017) [4]; permission conveyed through
Copyright Clearance Center, Inc.

1.3.2

Mild Cognitive Impairment

MCI is described in the literature as a pre-dementia state, as it is characterized by both
subjective memory complaints and objective decline on cognitive testing greater than
expected for normal aging [42]. To be diagnosed as MCI, patients must not have deficits
in their activities of daily living due to their changes in cognition, but they are at higher
risk for converting to dementia [42]. It is estimated that 10-20% of older adults over the
age of 65 meet these criteria for MCI [5]. While 5-15% of those with MCI may progress
to dementia each year, up to 30% of those with MCI will remain stable or revert back to
normal cognition [5,43]. MCI may present in many different cognitive domains, and
decline in each domain may present differently throughout the course of MCI [44]. In
general, MCI that affects any memory domains is termed amnestic MCI, while nonamnestic MCI affects other domains of cognition, usually including attention, executive
function, language or visuospatial skills [45]. MCI may also be present in more than one
domain (multi-domain MCI) or a single domain. While memory is the most commonly
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cited domain to have impairment in MCI, impairments of executive function are the
second most prevalent [5,46] and may also be associated with increased depression and
anxiety in patients with MCI[47].

1.3.3

Dementia

Dementia is a clinical syndrome resulting from several different underlying diseases
which cause chronic impairment in cognition [6]. Dementia diagnosis is also
characterized by subjective cognitive impairment, usually memory complaints with an
objective impairment on cognitive testing greater than expected for normal aging, both
affecting the patient’s activities of daily living [8,48]. The four major types of dementia
are Alzheimer’s Disease, Lewy Body Disease, Frontotemporal dementia, and vascular
dementia [49]. Alzheimer’s disease dementia is the most common of these and accounts
for 60-80% of total cases of dementia [50]. Five hundred sixty-four thousand Canadians
are currently living with dementia, which costs the Canadian healthcare system $10.4
billion annually [51]. In 2018, Alzheimer’s disease was the eighth highest overall cause
of death in Canada and the sixth highest for those aged 85 and older [52].
Currently, treatment options for dementia are limited. Pharmacological treatments are
aimed mainly at treating symptoms of the diseases, not the diseases themselves, and may
come with physical and neuropsychiatric side effects [53]. Many multi-domain treatment
studies including lifestyle interventions have shown promise in improving cognition in
patients with dementia, however these may have issues of adherence and often require
healthy lifestyle adaptation throughout the entire lifespan to show maximum benefits
[54]. Therefore, the search for in depth knowledge on the causes of dementia and
methods of early detection and diagnosis has become of the utmost importance in
research [55].

1.4

Gait

Gait can be defined as “the pattern of movement of the human body during locomotion”
[9]. Gait is commonly used to describe the manner or style of one’s walking [10], and is
one key component of overall mobility [56]. While there are normal fluctuations in gait
parameters, gait is generally stable between each stride even in changing external
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environments [57]. However, gait abnormalities are highly prevalent in older adults, both
in those with neurologic diseases and healthy older individuals [58]. Population based
studies estimate 30% of older adults over 60 have a gait disorder, but this may increase to
up to 60% for those over 80 years old [59,60]. Gait disturbances, known as a deviation
from a normal gait pattern, may be either continuous, when caused by an underlying
neuromuscular condition, or episodic, when in response to a change in the environment
[61]. Increased gait variability, or step-to step fluctuations in time or distance, may be
either of these, as it can be due to many conditions, such as stroke, neuropathy and
depression, or due to environmental changes, such as negotiating an obstacle or
performing multiple tasks at once [62]. Gait disturbances, and specifically high gait
variability, have been associated with future risk of falls [63–66], frailty [67], mobility
impairments and disability [68–70], and cognitive impairments and dementia [15,71–74].

1.4.1

Gait Cycle

The gait cycle is made up of both stance and swing phases (see Figure 1.2), with the
stance phase marking when the foot is on the ground, and the swing phase marking when
the foot is moving through the air [10,75]. The stance phase comprises about 60% of the
gait cycle, and begins and ends with both feet on the ground [76]. The swing phase makes
up the other 40% of the cycle, and begins with toe-off and ends with heel strike [76].
Once full gait cycle, or stride, is the interval between when one foot strikes the ground
until the same foot strikes the ground again [75].
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Figure 1.2 Phases of the gait cycle. From Kharb et al. (2011) [75]

1.4.2

Gait Assessment

Gait can be assessed by simple clinical observation or by quantitative testing.
Quantitative gait testing can be done using various technologies, such as video
recordings, electronic walkway, or accelerometer and wearable sensors. Gait testing
technologies can give extended information about a person’s walking and defined spatiotemporal quantitative variables can be assessed and recorded (see Table 1.1). For
example, computerized walkways using pressure sensors to detect each footprint have
become popular in research as they do not require a trained clinician and are highly
reliable [77,78]. However, these technologies may be too expensive and the outputs too
complex for use in clinical settings.
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Alternatively, clinical observation of gait has some benefits as well. Clinical observation
of gait includes an individual performing a number of walks while a trained clinician
observes one or more parameters of the individuals gait pattern. These parameters may
include: initiation, posture, gait speed/velocity, arm swing, freezing and more [76].
During clinical observation of gait, one important and clinically relevant quantitative
variable, gait speed, can simply be assessed using a stop watch and a marked path of a
known distance [14]. Using our previously published guidelines [14], gait testing can be
done in a clinical setting using a measured path on the floor (ideally six meters) and a
stop watch. While clinical observation of gait gives less quantitative information overall,
it can give clinicians useful information and it has been validated against traditional
technologies [79]. However, this approach may require more nuanced training for
assessment and classification of results.
Table 1.1 Definitions of Commonly Used Quantitative Spatiotemporal Gait
Variables. From Cullen et al. (2018) [14]
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1.4.3

Gait Speed

Gait speed can be defined as “the distance covered by the time to ambulate”, and is a
simple to collect but effective measure of mobility [14,80]. It can be measured using
either quantitative gait testing technologies, or the simple stop watch collection method
as described above. Gait speed has been described as the sixth vital sign in older adults
due to its sensitivity to detecting changes in different settings and clinical conditions [81–
83]. It was found that a decrease in gait speed of 0.1m/s was associated with poorer
health status and disability, while an increase of the same amount of associated with
overall well-being [82]. Gait speed has also been called the functional vital sign due to its
predictive abilities and ease of collection [83]. The term “bradypedia” has even been
suggested as a clinical diagnosis for slow gait speed [84].
Slow gait speed has also been associated with falls, limitations in activities of daily
living, dementia and even mortality [65,81,85–88]. In a pooled analysis of several large
cohort studies (n=27,220), a difference of 0.1m/s faster in gait speed was associated with
a decrease in risk of mobility disability by 26% in men and 27% in women (see Figure
1.3), and a decrease in risk of mortality over four years between 18% and 24% [89].
These associations between slow gait speed and poor cognitive function can already be
seen in midlife, and may even be related to poor development in childhood [90,91].
However, accelerated decline in gait speed in aging has been associated with an increase
in energy demands of walking, specifically due to changes in body composition, lower
extremity pain, poor balance, and other biomechanical and neuromuscular factors
[92,93].
While usual or self-selected gait speed is the most commonly studied, other
measurements of gait speed may be of interest. Maximum walking speed, where the
participant walks as fast as they can without running, has been suggested as a useful
measure in detecting changes in mobility performance and is associated with mobility
disability [14,83,94]. Additionally, gait speed while performing an added cognitive task,
or dual-task gait speed, has been associated with cognitive impairments and future risk of
cognitive decline [15,95,96].
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Changes in gait speed may be one of the earliest physical symptoms of dementia and are
associated with severity of the disease [97]. Therefore, tests of gait and motor
performance may be useful in detecting early signs of cognitive impairment, before
cognitive symptoms are detectable [98].

Figure 1.3 Gait speed in association with mobility difficulty for men (A) and women
(B). Used with permission of Oxford University Press, from Perera et al. (2016) [89]
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1.4.4

Gait and Cognition

While gait was once thought to be an automatic process requiring little cognitive input,
recent evidence has shown that gait and cognition may be more highly correlated than
once thought [38]. Firstly, gait performance and cognition both decline with age, and
large cohort studies have shown they often coexist in older adults [63,99–101]. Poor gait
performance has specifically been associated with low performance on tests of executive
function, as this higher level cognitive process collects information from the sensory
systems and uses it to produce and monitor behaviour and movements [20]. Gait
performance, particularly speed, has also been linked to other cognitive domains, such as
memory [102] and attention [39]. Additionally, decreased gait speed is one of the earliest
physical symptoms of dementia and may manifest years before cognitive impairments are
detectable [97].

1.5

Motor-Cognitive Interface

The presented evidence linking gait and cognition creates the theory of a motor-cognitive
interface (see Figure 1.4). This relationship between mobility and cognitive domains is
not fully understood yet [62], but it is known that regulation and control of gait and
cognitive processes rely on shared brain areas and networks that are susceptible to
damage during aging, diseases associated with aging, and neuropathology. Completing
both a motor and cognitive task at once can put stress on these systems and even overload
them if there are already cognitive challenges present. This overload can lead to deficits
in one or both tasks that can be measured, and provides an opportunity to use a dual-task
gait test as a “brain stress test” [14].
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Figure 1.4 (A) Traditional view of cognitive and gait decline with aging and (B) the
emerging view based on evidence of the cognitive-motor interface. From MonteroOdasso et al. (2012) [63]

1.5.1

Dual-Task Paradigm in Gait and Cognition Assessment

The dual-task paradigm suggests that two tasks done at the same time creates competition
between the two tasks for a limited amount of brain resources, and this competition
creates a detriment in one or more of the activities [20]. Dual-task gait testing, defined as
“walking while performing a cognitively demanding task”, applies this paradigm to the
interaction of mobility and cognition. Walking and cognitive tasks rely on shared
networks in the brain, and while these shared networks are also not fully known, the most
commonly described areas include the frontal lobe (ex. prefrontal and supplementary
motor areas) and temporal lobe (ex. hippocampus) [103–105]. This testing was derived
from a seminal study showing that nursing home residents who were not able to hold a
conversation while walking were at a higher risk of falls [106].
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1.5.2

Theories of Dual-Tasking

There are three main theories for how dual-tasking is processed in the brain. The first of
these is the capacity sharing model, which is based on the idea that attentional tasks
performed at the same time compete for a limited capacity of neural resources
[39,107,108]. The competing tasks can overload these resources, therefore causing the
disturbances we see in gait and cognitive tasks while dual-tasking [20]. The degree of this
effect, and in which of the two tasks it shows up in, is dependent on the type and
difficulty of both the cognitive task and the walking task [39,108]. The instructions given
can also influence which task is given priority (ie. higher attentional resource allocation)
[107], which is why in dual-task gait testing it is suggested to instruct participants to
equally prioritize both tasks [14] in order to best mimic what happens naturally while
walking [109,110].
A second theory of the processing of dual-tasking is the bottleneck theory, which
proposes that if two tasks require the same processor and that processor can only process
one task at a time, the second task is put on hold until the first is completed [107,108]. It
is also possible that multiple bottlenecks occur during the entire response process at
different stages, such as response selection and response execution [107,108].
Finally, a third theory of dual-tasking has to do with the similarities and differences
between the two tasks, and is called the cross-talk theory [108,111]. This theory relates to
decreasing peripheral overload, and postulates that similar tasks are more easily
processed together due to the “turning on” and use of similar processors [108]. For
example, it was found that performance in a rhythmic cognitive task, counting backwards
by ones, could be improved while walking when compared to just sitting, as walking also
has a rhythmic component [112]. However, there is some criticism of this theory that
suggests similar tasks processed together may cause side effects or “confusion” that
negatively affect performance [108].

1.5.3

Dual-Task Gait Cost

From dual-task gait testing we can calculate dual-task gait cost (DTGC), which is a
measure of the “cost” incurred by dual-tasking versus doing either the mobility or
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cognitive task alone (see Figure 1.5). DTGC measures how the added cognitive task
impairs gait performance, and can be calculated with any of the quantitative variables
collected in gait testing [14]. Dual-task cognitive cost (DTCC) can also be calculated,
depending on the cognitive task being completed, using response rate, number of correct
answers, or reaction time [14]. Older adults may prioritize gait and balance over
cognitive tasks [113], which cause DTCC to be larger than DTGC. However, DTGC for
gait speed is the more commonly reported measure of dual-task gait testing, without
consideration of DTCC, possibly due to differences in calculation of DTCC based on
type of cognitive task used and the difficulty of determining an accurate rate of
enumeration for the cognitive task, both by itself and while walking [114].

Figure 1.5 Visual representation of the dual-task cost calculation for gait speed.
Unpublished, used with permission from Dr. Manuel Montero-Odasso.

1.5.4

Studies of Dual-Task Gait Testing in a Clinical Setting and Current
Gaps in the Literature

To date, there are only three published studies of dual-task gait testing in a memory clinic
setting that we are aware of. The first of these was by MacAulay and colleagues [115],
which found patients with MCI made more cognitive errors while dual-tasking and
slowed down more when dual-tasking, in comparison to just walking, than healthy
controls (this was not quantified as dual-task cost but represents the same phenomenon).
Another study by Nielsen and colleagues [96] showed that dual-task cost using the Timed
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Up and Go test was able to separate healthy controls from patients with MCI and from
patients with dementia patients, but that it had a low prognostic value for future cognitive
decline. Furthermore, both of these studies had small sample sizes (n=61 and 86,
respectively), and these studies did not examine patients with a diagnosis of SCI. The
final study available was published by our group [116], and is a preliminary analysis of
the results that will be presented in this thesis. However, this previously published work
only included cross-sectional data and about half of the sample that will be presented
within this thesis. This previously published work concluded that using the three main
cognitive subtypes: SCI, MCI, and dementia, patients diagnosed with dementia had
slower gait speed and higher dual-task cost.

1.6
1.6.1

Overview of Thesis
Rationale

The presented literature supports the potential use of dual-task gait testing as a “stresstest” on the brain and its allocation of resources, which may be useful for detecting those
individuals at high-risk for future cognitive decline. Specifically, dual-task gait
performance was associated with progression to dementia in patients with MCI [15].
However, with only two relatively small studies of dual-task gait testing in clinical
settings [95,96], there exists a gap in the literature of a large, long-term clinical cohort
with a wider spectrum of cognitive diagnoses who are tested under multiple different
dual-tasks.

1.6.2

Purpose

The purpose of this thesis is to, within a clinical setting, 1) assess feasibility and
practicality of gait performance to help differentiate cognitive diagnoses, 2) assess
differences in gait speed and dual-task gait cost across the cognitive spectrum, and 3)
determine if poor gait performance at baseline is associated with future cognitive decline.

1.6.3

Hypotheses

At the cross-sectional level, it was hypothesized that 1) gait speed will be slower and
dual-task gait cost will be higher for older adults attending a memory clinic that are
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diagnosed with more severe cognitive impairment and 2) poorer performance on the dualtask gait assessment will be predictive of worse cognitive impairment.
Within the longitudinal sub-study, it was hypothesized that slow gait speed and higher
dual-task gait cost at baseline will be predictive of cognitive decline at the follow-up
visit.
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Chapter 2

2

Methods

We have previously published a sub-set of this data in the Journal of Alzheimer’s Disease
and the following methods have been adapted from this publication [116].

2.1

Study Design and Participants

Clinic-based study that included all consecutive older adults who were assessed for
memory complaints at the Aging Brain and Memory Clinic at Parkwood Institute in
London, Ontario, Canada between July 2015 and May 2019. In order to be included in
the current study, participants had to (1) be over 50 years of age, (2) be able to safely
ambulate six meters without an assistive device, and (3) be fluent in English and able to
understand test instructions. In order to be included in longitudinal analysis, participants
had to meet baseline inclusion criteria and have a second visit in the clinic minimum of
twelve months after their first visit. Follow-up visits in the clinic were usually scheduled
two to three years after the baseline visit. To maximize inclusion and to ensure an
accurate representation of the population seen in our clinics, no additional exclusion
criteria were used. Participants were grouped into three categories based on final
diagnosis: SCI, MCI and dementia. Diagnosis was achieved using a consensus
conference and established criteria (Petersen criteria for MCI [5] and the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition revised (DSM IV-TR) criteria for
dementia [8]) after assessment performed by a geriatrician specialized in cognitive aging
and dementia. Petersen criteria for MCI was ascertained by satisfying the following four
criteria i) subjective cognitive complaints; ii) objective cognitive impairment in at least
one of the following cognitive domains: memory, executive function, attention, and
language; iii) preserved activities of daily living; confirmed by a geriatrician specialized
in cognitive aging and dementia; iv) absence of dementia using criteria from the DSM
IV-TR. This study was approved by the Health Science Research Ethics Board at
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Western University and the Clinical Research Impact Committee at Lawson Health
Research Institute, both in London, Ontario, Canada.

2.2

Demographic and Clinical Variables

All participant information and gait testing results were collected from patient charts.
Demographic and clinical information collected included age, sex, falls history in the past
12 months, years of education, medications and comorbidities (see Appendix B).
Comorbidities were measured as total number of “yes” responses on a clinical
comorbidities checklist. Cognitive variables include Mini Mental State Examination
(MMSE) score and the Montreal Cognitive Assessment (MoCA) score.

2.3

Gait Testing Procedure

All gait assessments were performed at the start of the clinical visit in a hallway outside
the clinic room using a six-meter path. Six meters was chosen as it has been shown to be
an appropriate length to be used for older adults without mobility impairments to ensure
steady state walking is achieved [117]. Lines were marked on the floor to determine the
stop and start points. One meter was added to each end of the pathway (as shown in
Figure 2.1) to ensure acceleration and deceleration phases were not recorded. Walking
trials were timed using a handheld stopwatch and recorded to two decimal places. Speed
was calculated by dividing the known distance by the time spent walking from start to
end points marked on the floor, in each trial, for each participant, and then converted to
cm/s.
All participants were asked to complete a total of four walk trials. The first trial was
always the preferred or usual gait speed trial. For this trial, the participants were asked to
walk at their normal, every-day walking speed. The next three trials were the dual-task
walking trials, which comprised walking at usual speed while preforming an added
cognitively demanding task. The order of dual-task trials was fully randomized. The three
tasks used for this study were counting backwards by 1’s from 100 out loud, naming
animals out loud, and counting backwards by 7’s from 100 out loud, which have been
previously validated and are listed here in order of increasing cognitive demand [37,118–
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120]. Participants were instructed to equally prioritize both walking and the cognitive
task to accurately replicate normal daily activities[20,109]. Number of enumerations and
errors per each dual-task trial was also recorded in the patient’s chart along with the
speed for each trial. Participants were included in the analysis as long as they completed
the usual gait speed trial and at least one of the dual-task trials. This gait protocol
followed the Canadian guidelines for gait assessment we have published [14].

Figure 2.1 View of the gait testing pathway used in the Aging Brain and Memory
Clinic. From Cullen et al. (2018) [14]

2.4

Feasibility Measures

For cross-sectional feasibility investigations, both quantitative and qualitative measures
were used. Participant agreement was measured quantitatively as the percentage of
eligible participants who completed a gait assessment at the clinic visit. Participants were
included if they completed the usual gait walk and at least one dual-task walk. In order to
establish the feasibility and practicality of gait testing in a busy clinical setting, after the
study was completed we surveyed the two primary assessors who completed the gait
testing. Assessor satisfaction was measured using the following questions:
Using a Likert scale from 1 (‘Very Easy’) to 5 (‘Very Hard’):
1) How easy was the dual-task gait assessment to complete?
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2) How easily was the dual-task gait assessment integrated into the flow and timing of the
clinic appointment?
There was also the option to add additional comments to any of the ratings given above.

2.5

Calculation of Dual-Task Gait Cost (DTC)

DTC was calculated for each dual-task trial using the appropriate velocities. DTC was
calculated in Microsoft Excel 2010 using the following formula: DTC = [(usual gait
speed – dual-task gait speed)/usual gait speed] x 100. DTC is expressed as a percentage
of slowing from the usual gait speed as a result of the added cognitive task [121]. For this
thesis, DTC will refer only to dual-task gait cost, as dual-task cognitive cost was not
examined.

2.6

Outcome Variables and Criteria

Following the objective of this thesis to determine if poor baseline gait performance was
associated with future cognitive decline, three outcome variables were used to quantify
cognitive decline at the follow-up visit. The first of these was a progression to a more
severe diagnosis of cognitive impairment, which was categorized as conversion from SCI
to MCI or dementia, MCI to dementia, or early/prodromal dementia to moderate or
severe dementia. While this outcome is important for clinical use and for comparison to
other studies measuring conversion to dementia [15,71], there is an inherent
heterogeneity in these various changes and the potential for subjective bias. For example,
conversion from MCI to dementia, based on some criteria, can be a result of the patient
themselves or their caregiver reporting a change in activities of daily living (ADLs) and
not due to changes in cognition [122–124]. For this reason, we have also decided to
investigate if gait performance predicts decline in scores on cognitive tests, specifically
the Mini Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA).
These objective measures have been thoroughly studied, and it was determined based on
previous studies that cognitive decline would be operationalized as a drop of greater than
two points per year on the MoCA [72,125]. For example, it was previously found in a
study of MCI patients that the mean drop in total MoCA score was 2.19 points per year in
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those who eventually converted to dementia and 1.72 points per year for those who
remained MCI [125]. Estimates of average rate of decline on the MMSE vary and have
been reported between less than one point per year for older people with normal
cognition [126] and up to and over four points per year for patients with dementia [127–
129]. Given the mixed diagnosis groups in our sample and to remain consistent with our
criteria for MoCA decline, this outcome variable was also operationalized as a drop of
greater than two points per year. Given the average follow-up period in our sample is at
least two years, these values are also consistent with the minimal detectable change of
three points on the MMSE and four points on the MoCA [130].

2.7

Statistical Analyses

Data were checked for normality and homogeneity of variances using the KolmogorovSmirnov and Levene’s tests, respectively. Demographic and clinical characteristics were
summarized as means and standard deviations or frequencies and percentages, as
appropriate. Baseline demographic characteristics were compared between groups using
one-way analysis of variance (ANOVA) or Chi-Square tests. Statistical significance was
set at p<0.05. Statistical analyses were conducted using SPSS, version 25 (IBM
Corporation).

2.7.1

Cross-sectional Analyses

Gait speed and dual-task gait cost were compared across groups using a repeated
measures two-way analysis of variance (ANOVA), both unadjusted and adjusted for age,
to evaluate the effect of cognitive diagnosis (diagnosis) across the different gait tasks
(task) and their interaction (diagnosis x task).
The association between gait performance and diagnosis of an objective cognitive
impairment MCI or dementia) was analyzed using a multi-factor regression with SCI as
the reference category, with gait speed and dual-task cost as the independent variables
and adjusted for age and sex. The association between gait performance and dementia
diagnosis was also analyzed using a logistic regression, with dementia and pre-dementia
(SCI or MCI) as the dichotomous outcome variable.
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Receiver Operating Curves (ROC curves) with corresponding area under the curve
(AUC) were created to determine the optimal cut-off point for slow gait speed in each
gait test. AUC was classified using the clinical categorizations of low accuracy (0.5-0.7),
moderate accuracy (0.7-0.9) and high accuracy (0.9 and higher). Moderate accuracy (0.7
or higher) is considered clinically relevant [131]. Sensitivity and specificity were
determined for each cut-off point from these curves. Association between dementia
diagnosis and slow gait speed using these cut-off points was assessed using a binary
logistic regression.

2.7.2

Longitudinal Analyses

Cox regression analyses were completed to assess risk of progressing to a worse
diagnosis, as measured by hazards ratios (HR), based on gait performance (usual and
dual-task gait speed and dual-task cost) as continuous and dichotomous variables. Cut-off
values for gait speed and dual-task cost were set at the mean of each variable for the
sample. Proportional hazards were checked using visual inspection of Kaplan-Meier
curves. Time was calculated as the number of months between the baseline visit and the
follow-up visit in the clinic. To account for different follow-up periods, decline on
cognitive tests was measured as points per year decline.

25

Chapter 3

3

Cross-Sectional Gait Performance and Measurement in a
Clinical Setting

This chapter will explore the use of gait testing in a memory clinic setting from a crosssectional standpoint. Specifically, this chapter will focus on the previously stated goals of
this thesis, to determine 1) differences in gait speed and dual-task gait cost across the
cognitive spectrum in a clinical setting and 2) if measuring gait performance is feasible in
a clinic setting and useful to help differentiate cognitive diagnoses.

3.1
3.1.1

Results
Participant Characteristics

Three hundred seventy-two participants (mean age 72.83 ± 10.05 years; 50.8% female)
met inclusion criteria. This sample included eighty-one participants with SCI, one
hundred fifty-five participants with MCI and one hundred thirty-six with dementia.
Characteristics of the study sample stratified by cognitive diagnosis are presented in
Table 3.1. Mean age of participants was significantly higher across the spectrum of
cognitive impairment. As expected, MMSE and MoCA scores were significantly lower in
groups with more severe cognitive impairment diagnosis. The SCI group had
significantly higher years of education than both the MCI and dementia groups. All three
groups had similar number of comorbidities, number of medications, and twelve month
falls histories.

26

Table 3.1 Demographic and clinical characteristics of study participants in sample
stratified by cognitive diagnosis
Stratified by Cognitive Diagnosis
Variable

Total Cohort
(n=372)

SCI
(n=81)

MCI
(n=155)

Dementia
(n=136)

p-value

Age (mean, SD)

72.83 (10.05)

65.57 (10.38) 71.97 (9.30)

78.13 (7.38)

<0.001

Female (n, %)

189 (50.8%)

47 (58.0%)

75 (48.4%)

69 (50.7%)

0.281

Years of education
(mean, SD)

12.7 (3.4)b

14.0 (3.1)c

12.3 (3.3)d

12.3 (3.5)e

0.001a

No. of
Comorbidities
(mean, SD)

5.7 (3.3)

5.6 (3.7)

5.9 (3.2)

5.5 (3.1)

0.636

No. of medications 7.9 (4.5)
(mean, SD)

8.0 (5.0)

7.8 (4.3)

8.0 (4.3)

0.921

MMSE score
(mean, SD)

25.4 (4.6)f

29.0 (1.6)

26.6 (2.8)g

21.8 (4.9)

<0.001a

MoCA score
(mean, SD)

21.1 (5.0)h

26.8 (2.0)i

21.1 (3.6)j

16.8 (4.0)k

<0.001a

276 (74.2%)

63 (77.8%)

119 (76.8%)

94 (69.1%)

0.230

22 (14.2%)
14 (9.0%)

23 (16.9%)
19 (14.0%)

Falls (n, %)l
No falls

1 fall
59 (15.9%)
14 (17.3%)
2+ falls
37 (9.9.1%)
4 (4.9%)
Statistically significant values are bolded.

Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment.
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment.
a,

p-value reported from Welch’s Test for unequal variance.

b,

data available for n=332.

c,

data available for n=74.

d,

data available for n=143.

e,

data available for n=115.
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f,

data available for n=370.

g,

data available for n=153.

h,

data available for n=339.

i,

data available for n=80.

j,

data available for n=152.

k,

data available for n=107.

l,

in the past 12 months only.
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3.1.2

Differences in Gait Speed Across the Diagnosis Groups

Gait speed for each group in each gait condition is summarized in Figure 3.1, Figure 3.2,
and Table 3.2. Gait speed was lower in each group from usual gait to dual-tasking and
with increasing dual-task difficulty. The repeated-measures ANOVA was significant
when unadjusted and adjusted for age. Post-hoc analysis revealed that in the usual gait,
counting backwards and naming animals tasks, the SCI and MCI groups were statistically
similar to each other, but the dementia group was significantly different from both of
those groups. In the serial sevens condition, only the SCI and dementia groups were
statistically different (p=0.01). Within groups analysis showed that in the SCI and
dementia groups the counting backwards and naming animals tasks were statistically
similar (p=0.07 and p=0.31, respectively). All other within groups comparisons were
significantly different (p<0.05).

Figure 3.1 Gait speed (cm/s) stratified by diagnosis group
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Figure 3.2 Gait speed (cm/s) stratified by gait condition
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Table 3.2 Gait Speed performance (cm/s) by cognitive diagnosis and gait condition
Gait
Condition
[mean (SD)]
Usual gait

Total
cohort
(n=296)

SCI
(n=74)

MCI
(n=128)

Dementia
(n=94)

102.69

111.39

106.27

90.96 (23.13)

(24.64)

(24.19)

(22.89)

Counting

83.02

91.63

87.01 (22.26)

70.79 (21.83)

backwards

(24.25)

(24.72)

Naming

76.42

85.02

79.26 (21.04)

65.79 (22.11)

animals

(23.11)

(23.03)

Serial sevens

62.98

68.61

65.14 (19.77)

55.61 (20.25)

(21.22)

(22.51)

Statistically significant values are bolded.
n=76 excluded due to missing data in one or more gait conditions.
Model 1: Unadjusted. Model 2: Adjusted for age.
p-values reported are using the Greenhouse-Geisser correction for sphericity.

Effects
p-value
Model 1

Effects
p-value
Model 2

Diagnosis: <0.001

Diagnosis: <0.001

Condition: <0.001

Condition: <0.001

Interaction
(Diagnosis*Condition): 0.04

Interaction
(Diagnosis*Condition): 0.21
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3.1.3

Differences in Dual-Task Gait Cost (DTC) Across the Diagnosis
Groups

DTC for each group is summarized in Figure 3.3, Figure 3.4, and Table 3.3. The repeated
measures ANOVA showed that DTC performance was only significantly associated with
which dual-task condition was being performed (p<0.001). Within each diagnosis group,
DTC increased with increasing task difficulty. There was no statistically significant
difference in DTC between diagnosis groups (p=0.43).

Figure 3.3 Dual-task gait cost (%) stratified by diagnosis group
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Figure 3.4 Dual-task gait cost (%) stratified by gait condition
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Table 3.3 Dual-task Cost (%) by cognitive diagnosis and gait condition
Gait
Condition
[mean (SD)]

Total cohort
(n=296)

SCI
(n=74)

Counting

18.94 (14.62)

17.47 (15.30)

MCI
(n=128)
18.13 (12.23)

Dementia
(n=94)
21.21 (16.81)

backwards
Naming

25.21 (15.65)

23.26 (24.95)

24.95 (14.72)

27.14 (16.81)

animals
Serial sevens

38.13 (17.39)

37.60 (18.41)

38.41 (17.32)

38.18 (16.86)

Statistically significant values are bolded.
n=76 excluded due to missing data in one or more gait conditions.
Model 1: Unadjusted. Model 2: Adjusted for age.
p-values reported are using the Greenhouse-Geisser correction for sphericity.

Effects
p-value
Model 1

Effects
p-value
Model 2

Diagnosis: 0.43

Diagnosis: 0.10

Condition: <0.001

Condition: 0.03

Interaction

Interaction

(Diagnosis*Condition): 0.40

(Diagnosis*Condition): 0.30
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3.1.4

Association between Gait Performance and Objective Cognitive
Impairments

The association between gait performance on each dual-task condition and cognitive
diagnosis was examined with SCI as the reference level (Table 3.4). For all gait
conditions, MCI and SCI were statistically similar, except for gait speed in the naming
animals condition, where slower speed was associated with an MCI diagnosis (presented
as 1/exp(B): OR=1.01; 95% CI=1.00-1.02; p= 0.048). In contrast, poor performance
(slower speed and higher DTC) was associated with diagnosis of dementia in almost all
gait conditions. The exception to this was dual-task cost in the serial sevens condition,
which was not associated with higher risk of dementia diagnosis (OR=1.01; CI=0.991.03; p=0.46).
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Table 3.4 Association between gait performance and cognitive impairment (MCI or
Dementia) vs subjective impairment (SCI)
Gait Condition

Odds Ratio (95% CI)

p-value

MCI

1.00 (0.99-1.01)

0.66

Dementia

1.02 (1.01-1.04)

0.001

MCI

1.01 (1.00-1.02)

0.16

Dementia

1.05 (1.03-1.06)

<0.001

MCI

1.01 (0.99-1.03)

0.25

Dementia

1.04 (1.02-1.06)

<0.001

MCI

1.01 (1.00-1.02)

0.048

Dementia

1.04 (1.02-1.06)

<0.001

MCI

1.02 (1.00-1.03)

0.09

Dementia

1.03 (1.01-1.05)

0.001

MCI

1.01 (0.99-1.02)

0.42

Dementia

1.03 (1.01-1.04)

0.004

MCI

1.01 (0.99-1.02)

0.51

Dementia

1.01 (0.99-1.03)

0.46

Usual gait speed

Counting backwards
Speed

Dual-Task Gait Cost

Naming animals
Speed

Dual-Task Gait Cost

Serial sevens
Speed

Dual-Task Gait Cost

Statistically significant values are bolded.
SCI is the reference category.
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Adjusted for age and sex.
For speed, Odds Ratio presented as 1/Exp(B).

37

3.1.5

Association between Gait Performance and Dementia Diagnosis

Based on the previous results, the association with gait performance was also compared
between dementia and the pre-dementia states (SCI and MCI) (Table 3.5). Again, slower
gait speed and higher dual-task cost were significantly associated with dementia
diagnosis in all gait conditions, except for dual-task cost in the serial sevens condition
(OR=1.00; 95% CI=1.00-1.02; p=0.675).
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Table 3.5 Association between gait performance and dementia diagnosis
Gait Condition

Odds Ratio (95% CI)

p-value

1.02 (1.01-1.03)

<.001

Speed

1.04 (1.02-1.05)

<.001

Dual-task gait cost

1.03 (1.02-1.05)

<.001

Speed

1.03 (1.02-1.04)

<.001

Dual-task gait cost

1.02 (1.01-1.04)

0.004

Speed

1.02 (1.01-1.04)

0.003

Dual-task gait cost

1.00 (1.00-1.02)

0.675

Usual gait
Speed
Counting backwards

Naming animals

Serial sevens

Statistically significant values are bolded.
Adjusted for age and sex.
For speed, Odds Ratio presented as 1/Exp(B).
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3.1.6

Optimal Cut-off Values for Gait Speed

ROC Curve analysis showed a moderate ability to separate dementia patients from predementia diagnoses for all gait conditions (Figure 3.5 and Table 3.6). While the AUC for
each of the four gait tests were all statistically significant (p<0.001), only the counting
backwards condition had moderate accuracy (AUC=0.711). The naming animals
(AUC=0.698) and usual gait (AUC=0.693) conditions had low accuracy just below the
moderate accuracy cut-off (AUC > 0.7). The optimal cut-off points for each gait test were
as follows: 99.18 cm/s for usual gait, 80.54 cm/s for counting backwards, 82.72 cm/s for
naming animals and 71.85 cm/s for serial sevens. These all gave moderate sensitivity
(62.8%-72.3%) and specificity (60.0%-64.9%).
Using these cut-off values, a dichotomous gait variable was created (slow or fast gait
speed). Binary logistic regression showed that slow gait speed was significantly
associated with dementia diagnosis in all gait conditions (Table 3.7). The highest odds
ratio was for speed while counting backwards (OR=3.73; 95% CI=2.22-6.26; p<0.001),
while the lowest was for usual gait speed (OR=1.70; 95% CI=1.04-2.76; p=0.034).
Naming animals and serial sevens were both in between these [NA(OR=2.73; 95%
CI=1.54-4.82; p=0.001); S7 (OR=1.97; 95% CI=1.06-3.68; p=0.033)].
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Figure 3.5 Receiver-operating characteristic (ROC) curves for gait speed’s ability to
separate dementia from SCI and MCI patients in each gait condition

Table 3.6 Gait speed cut-off values and associated sensitivity, specificity, and area
under the curve (AUC) for each gait condition
Gait
Condition

Optimal Cut-Off
point (cm/s)

Sensitivity

Specificity

p-value

64.0%

Area Under
the Curve
(AUC)
.693

Usual gait

99.18

62.8%

Counting
backwards
Naming
animals
Serial sevens

80.54

70.2%

62.9%

.711

<.001

82.72

72.3%

60.0%

.698

<.001

71.85

63.8%

64.9%

.657

<.001

Statistically significant values are bolded.

<.001

41

Table 3.7 Association between slow gait speed on each test condition and dementia
diagnosis
Gait Condition
Usual gait

Odds Ratio (95% CI)
1.70 (1.04-2.76)

p-value
0.03

Counting backwards

3.73 (2.22-6.26)

<.001

Naming animals

2.73 (1.54-4.82)

0.001

Serial sevens

1.97 (1.06-3.68)

0.03

Statistically significant values are bolded.

42

3.1.7

Feasibility Measures

There were four hundred sixty-seven clinic visits marked as eligible during the study
period. Of these, forty-three charts were missing from the clinic at the time of data
collection. The total number of charts accessed was four hundred twenty-four. Fifty-two
participants were excluded from data collection for reasons summarized in Table 3.8. The
most common reason gait testing was not done was due to barriers of the participants
(59.6%), including communication issues (28.8%) and being unable to ambulate the path
freely (23.1%). Assessor issues accounted for 13.5% of those participants who could not
be included. The final study sample (n=372) represents 87.7% of the total potential
participants who had data available, showing that gait testing can be successfully
performed in a large majority of clinic patients.
Results from the feasibility survey of the assessors who completed the dual-task gait
testing in the clinic are summarized in Table 3.9. Overall, both the physician and nurse
clinician said that gait testing was “pretty easy” or 2 on a 5-point Likert scale for both
ease of completing the test and ease of integrating it into the clinic visit. The additional
comments made suggested that the gait collection form (see Appendix C), physical space
to perform the test, and the timing of the appointment were all important aspects to
successfully complete the test.
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Table 3.8 Reasons for exclusion from study for patients with an eligible clinic visit
and available data
Reason for Exclusion

n

%

Participant issues

31

59.6

Using gait aid/unable to walk

12

23.1

Communication issues/language barrier

15

28.8

Refused

1

2.0

Shortness of breath/cannot exert

3

5.8

7

13.5

No trained assessor available

4

7.7

Incorrectly recorded

3

5.8

11

21.2

Under age limit (50 years old)

8

15.4

Not in one of three diagnosis groups

3

5.8

3

5.8

Assessor issues

Study criteria

Reason not listed
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Table 3.9 Assessor feedback on feasibility of the dual-task gait assessment

Assessor’s Position

Ease of completing the
assessment

Ease of integrating
the assessment into
the flow and timing of
the clinic
appointment

Memory Clinic
Physician

2 - “pretty easy”

2 - “pretty easy”

Nurse Clinician

2 - “pretty easy”

2 - “pretty easy”

Additional Comments

“is relatively easy to
complete with the
template form”
“Space in an office
setting may be a limiting
factor”
“Sometimes it’s a
challenge… depending
upon how [early] patients
arrive/ [how busy it is at]
time of arrival”

Notes: Numeric responses collected on a 5-point Likert Scale.
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Chapter 4

4

Longitudinal Analysis

Poor gait performance, as indicated by slow gait speed and high dual-task cost, has been
associated with future risk of falls and cognitive decline [15,106]. As gait testing can be a
cost effective and easy to measure clinical marker, it may act as a complement to current
cognitive assessments to detect those at high risk for future cognitive decline. This
chapter will explore the relationship between poor gait performance at baseline and
cognitive status at the next clinical follow-up at least one year later. The three outcome
variables explored for cognitive status at follow-up visit are 1) progression to a more
severe diagnosis, which was categorized as conversion from SCI to MCI or dementia,
MCI to dementia, or early/prodromal dementia to moderate or severe dementia 2) global
cognitive decline of >2 points per year on the MoCA and 3) global cognitive decline of
>2 points per year on the MMSE.

4.1
4.1.1

Results
Participant Characteristics

One hundred and seven patients met baseline inclusion criteria and had a second clinic
visit at least twelve months later but still within the study period. Of these, nineteen had a
baseline diagnosis of SCI, fifty-one had a baseline diagnosis of MCI, and thirty-seven
had a baseline diagnosis of dementia. Sixty-one participants had progressed to a more
severe diagnosis at their follow-up visit, while forty-six participants had remained stable
or improved at follow-up. Characteristics of the study sample stratified by diagnosis
change status are shown in Table 4.1. Participants who progressed in diagnosis and those
who were stable were statistically similar in all baseline variables.
Characteristics of the study sample stratified by decline on cognitive testing are shown in
Table 4.2 and Table 4.3. Twenty-nine participants showed significant decline in MoCA
performance at follow-up (>2 points per year). Fifteen participants were missing MoCA
score at one or both visits and therefore decline could not be calculated. Participants who
showed significant decline on the MoCA and those who did not were statistically similar
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in all baseline variables. Thirty participants showed significant decline on MMSE (>2
points per year). Participants who showed decline on MMSE testing were significantly
older, had worse baseline cognitive test scores, and more severe baseline cognitive
diagnosis.
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Table 4.1 Baseline demographic and clinical characteristics of study participants in
sample stratified by follow-up diagnosis status
Stratified by Diagnosis Status
Variable

Total Cohort
(n=107)

Stable/improved
diagnosis
(n=46)

Progression in
diagnosis
(n=61)

p-value

Age (mean, SD)

73.11 (9.47)

71.46 (10.60)

74.25 (8.43)

0.17a

Female (n, %)

57 (53.3%)

27 (58.7%)

30 (49.2%)

0.33

12.80 (3.01)b

12.34 (2.95)c

13.16 (3.03)d

0.18

No. of
Comorbidities
(mean, SD)

5.94 (2.99)

6.39 (2.71)

5.60 (3.15)

0.18

No. of medications
(mean, SD)

8.28 (3.86)

8.56 (4.34)

8.06 (3.48)

0.52a

MMSE score
(mean, SD)

25.76 (4.01)

26.57 (3.71)

25.15 (4.16)

0.07

MoCA score
(mean, SD)

20.76 (5.18)e

21.76 (4.95)f

19.98 (5.25)g

0.08

19 (17.8%)

10 (21.7%)

9 (14.8%)

0.57

MCI

51 (47.6%)

22 (47.8%)

29 (47.5%)

Dementia

37 (34.6%)

14 (30.4%)

23 (37.7%)

Years of education
(mean, SD)

Baseline diagnosis
(n, %)
SCI

Statistically significant values are bolded.
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment.
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment.
a,

p-value reported from Welch’s Test for unequal variance.

b,

data available for n=99.

c,

data available for n=44.

d,

data available for n=55.
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e,

data available for n=103.

f,

data available for n=45.

g,

data available for n=58.
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Table 4.2 Baseline demographic and clinical characteristics of study participants in
sample stratified by follow-up MoCA change status
Stratified by MoCA score change
Variable

Total Cohort
(n=92)

Stable or normal
decline
(n=63)

Accelerated
decline
(n=29)

p-value

Age (mean, SD)

72.54 (9.54)

71.76 (10.22)

74.24 (7.75)

0.20a

Female (n, %)

51 (55.4%)

37 (58.7%)

14 (48.3%)

0.35

12.78 (2.96)b

12.38 (2.61)c

13.69 (3.51)d

0.10a

No. of
Comorbidities
(mean, SD)

6.18 (2.83)

5.85 (2.73)

6.90 (2.96)

0.10

No. of
medications
(mean, SD)

8.46 (3.98)

8.68 (4.45)

7.96 (2.68)

0.34a

MMSE score
(mean, SD)

26.55 (3.40)

26.60 (3.84)

26.45 (2.23)

0.84

MoCA score
(mean, SD)

21.34 (5.04)

21.16 (5.33)

21.72 (4.40)

0.62

19 (20.6%)

14 (22.2%)

5 (17.2%)

0.86

MCI

45 (48.9%)

30 (47.6%)

15 (51.7%)

Dementia

28 (30.4%)

19 (30.2%)

9 (31.0%)

Years of
education
(mean, SD)

Baseline
diagnosis (n, %)
SCI

Statistically significant values are bolded.
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment.
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment.
a,

p-value reported from Welch’s Test for unequal variance.

b,

data available for n=86.

c,

data available for n=60.
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d,

data available for n=26.
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Table 4.3 Baseline demographic and clinical characteristics of study participants in
sample stratified by follow-up MMSE change status
Stratified by MMSE score change
Variable

Total Cohort
(n=107)

Stable or normal
decline
(n=77)

Accelerated
decline
(n=30)

p-value

Age (mean, SD)

73.11 (9.47)

71.99 (9.78)

76.00 (8.09)

0.048

Female (n, %)

57 (53.3%)

45 (58.4%)

12 (40.0%)

0.09

12.80 (3.01)b

12.81 (3.16)c

12.76 (2.59)d

0.94

No. of
Comorbidities
(mean, SD)

5.94 (2.99)

6.12 (2.79)

5.50 (3.45)

0.34

No. of
medications
(mean, SD)

8.28 (3.86)

8.45 (4.10)

7.83 (3.18)

0.41a

MMSE score
(mean, SD)

25.76 (4.02)

26.44 (3.74)

24.00 (4.22)

0.004

MoCA score
(mean, SD)

20.76 (5.18)e

21.92 (5.08)f

17.48 (3.97)g

<0.001

19 (17.8%)

19 (24.7%)

0 (0.0%)

0.003

MCI

51 (47.6%)

37 (48.0%)

14 (46.7%)

Dementia

37 (34.6%)

21(27.3%)

16 (53.3%)

Years of
education
(mean, SD)

Baseline
diagnosis (n, %)
SCI

Statistically significant values are bolded.
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment.
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment.
a,

p-value reported from Welch’s Test for unequal variance.

b,

data available for n=99.

c,

data available for n=74.
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d,

data available for n=25.

e,

data available for n=103.

f,

data available for n=76.

g,

data available for n=27.
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4.1.2

Gait Performance and Association with Progression in Cognitive
Diagnosis

Table 4.4 reports the association between progression in cognitive diagnosis and gait
speed and DTC as continuous variables as determined by the cox regression models.
Only performance on the naming animals dual-task test was significantly associated with
future decline in cognitive diagnosis. Both gait speed (presented as 1/exp(B): HR=1.02;
95% CI=1.00-1.03; p=0.004) and DTC (HR=1.02; 95% CI=1.01-1.04; p=0.011) in the
naming animals condition were associated with diagnosis progression. These associations
remained significant when adjusted for age, sex, and comorbidities. Performance in usual
gait speed and the other dual-tasks were not significantly associated with the outcome
variable.
Modeling gait speed and DTC as dichotomous variables using a mean split showed that
only slow gait speed on the naming animals dual-task condition was associated with
diagnosis progression (HR=1.73; 95% CI=1.03-2.91; p=0.037) (Table 4.5). This
association did not remain significant when adjusted for covariates.
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Table 4.4 Cox proportional hazard regression of the association of continuous gait
speed and dual-task cost with cognitive diagnosis progression
Model 1 (Unadjusted)
Variable

Model 2 (Adjusted)

HR (95% CI)

p-value

HR (95% CI)

p-value

Usual

1.01 (0.99-1.02)

0.31

1.00 (0.99-1.01)

0.80

Counting backwards

1.01 (1.00-1.02)

0.08

1.01 (1.00-1.02)

0.14

Naming animals

1.02 (1.00-1.03)

0.004

1.02 (1.00-1.03)

0.01

Serial sevens

1.01 (0.99-1.02)

0.38

1.00 (0.99-1.02)

0.55

Counting Backwards

1.01 (0.99-1.02)

0.39

1.01 (1.00-1.03)

0.15

Naming animals

1.02 (1.01-1.04)

0.01

1.02 (1.01-1.04)

0.008

Serial sevens

1.00 (0.98-1.02)

0.88

1.01 (0.99-1.02)

0.61

Speed

Dual-Task Cost

Statistically significant values are bolded.
Abbreviations: HR = Hazard ratio.
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.
For gait speed, Hazard Ratio presented as 1/Exp(B).
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Table 4.5 Cox proportional hazard regression of the association of dichotomous gait
speed and dual-task cost with cognitive diagnosis change
Model 1 (Unadjusted)
Variable

Model 2 (Adjusted)

HR (95% CI)

p-value

HR (95% CI)

p-value

Usual (<102.6cm/s)

1.26 (0.76-2.09)

0.38

1.12 (0.65-1.93)

0.68

Counting backwards
(<81.6cm/s)

1.05 (0.63-1.77)

0.84

1.15 (0.68-1.96)

0.60

Naming animals
(<75.1cm/s)

1.73 (1.03-2.91)

0.04

1.60 (0.94-2.72)

0.09

Serial sevens
(<60.7cm/s)

1.22 (0.69-2.16)

0.49

1.07 (0.60-1.94)

0.81

Counting Backwards
(>21.1%)

1.19 (0.71-2.00)

0.51

1.45 (0.85-2.49)

0.17

Naming animals
(>27.0%)

1.50 (0.90-2.50)

0.12

1.57 (0.97-2.63)

0.09

Serial sevens (>41.0%)

1.15 (0.65-2.00)

0.62

1.28 (0.72-2.29)

0.40

Speed

Dual-Task Cost

Statistically significant values are bolded.
Abbreviations: HR = Hazard ratio.
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.
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4.1.3

Gait Performance and Association with Decline on the Montreal
Cognitive Assessment (MoCA)

Table 4.6 shows the association between continuous gait variables and decline on the
Montreal Cognitive Assessment (MoCA). Higher DTC in the naming animals condition
was significantly associated with decline on the MoCA (HR=1.03; 95% CI=1.00-1.05;
p=0.027). This association remained significant when adjusted for age, sex, and
comorbidities. No other gait variables showed a significant association with decline on
the MoCA.
When modeled as dichotomous variables, none of the gait variables were significantly
associated with future decline on the MoCA (Table 4.7).
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Table 4.6 Cox proportional hazard regression of the association of continuous gait
speed and dual-task cost with MoCA score decline
Model 1 (Unadjusted)
Variable

Model 2 (Adjusted)

HR (95% CI)

p-value

HR (95% CI)

p-value

Usual

1.00 (0.98-1.02)

0.99

0.99 (0.97-1.01)

0.31

Counting backwards

1.01 (1.00-1.03)

0.18

1.01 (0.99-1.02)

0.43

Naming animals

1.01 (1.00-1.03)

0.08

1.01 (0.99-1.03)

0.25

Serial sevens

1.01 (0.99-1.03)

0.24

1.01 (0.99-1.03)

0.56

Counting Backwards

1.02 (0.99-1.04)

0.16

1.02 (1.00-1.04)

0.13

Naming animals

1.03 (1.00-1.05)

0.03

1.02 (1.00-1.05)

0.03

Serial sevens

1.02 (0.99-1.04)

0.22

1.01 (0.99-1.04)

0.27

Speed

Dual-Task Cost

Statistically significant values are bolded.
Abbreviations: MoCA= Montreal Cognitive Assessment. HR = Hazard ratio.
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.
For gait speed, Hazard Ratio presented as 1/Exp(B).
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Table 4.7 Cox proportional hazard regression of the association of dichotomous gait
speed and dual-task cost with MoCA score decline
Model 1 (Unadjusted)
Variable

Model 2 (Adjusted)

HR (95% CI)

p-value

HR (95% CI)

p-value

Usual (<102.6cm/s)

1.21 (0.58-2.51)

0.61

0.98 (0.44-2.15)

0.95

Counting backwards
(<81.6cm/s)

1.35 (0.64-2.83)

0.43

1.32 (0.60-2.90)

0.49

Naming animals
(<75.1cm/s)

1.71 (0.82-3.59)

0.15

1.56 (0.72-3.36)

0.26

Serial sevens
(<60.7cm/s)

2.16 (0.93-5.01)

0.08

1.72 (0.71-4.16)

0.23

Counting Backwards
(>21.1%)

1.54 (0.74-3.20)

0.24

1.67 (0.79-3.55)

0.18

Naming animals
(>27.0%)

1.65 (0.79-3.43)

0.18

1.71 (0.82-3.59)

0.16

Serial sevens (>41.0%)

1.77 (0.78-4.00)

0.17

1.76 (0.74-4.15)

0.20

Speed

Dual-Task Cost

Statistically significant values are bolded.
Abbreviations: MoCA= Montreal Cognitive Assessment. HR = Hazard ratio.
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.
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4.1.4

Gait Performance and Association with Decline on the Mini Mental
State Exam (MMSE)

Table 4.8 shows the association between continuous gait variables and decline on the
Mini Mental State Exam (MMSE). Slower gait speed in the naming animals condition
was significantly associated with decline on the MMSE (presented as 1/exp(B):
HR=1.02; 95% CI=1.00-1.04; p=0.01). This association remained significant when
adjusted for age, sex, and comorbidities. No other gait variables showed a significant
association with decline on the MoCA.
When modeled as dichotomous variables, none of the gait variables were significantly
associated with future decline on the MMSE (Table 4.9).
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Table 4.8 Cox proportional hazard regression of the association of continuous gait
speed and dual-task cost with MMSE score decline
Model 1 (Unadjusted)
Variable

Model 2 (Adjusted)

HR (95% CI)

p-value

HR (95% CI)

p-value

Usual

1.01 (1.00-1.03)

0.16

1.01 (0.99-1.02)

0.48

Counting backwards

1.01 (0.99-1.03)

0.20

1.01 (0.99-1.02)

0.43

Naming animals

1.02 (1.00-1.04)

0.01

1.02 (1.00-1.04)

0.04

Serial sevens

1.02 (0.99-1.04)

0.15

1.01 (0.99-1.03)

0.38

Counting Backwards

1.00 (0.98-1.03)

0.78

1.01 (0.98-1.03)

0.59

Naming animals

1.02 (1.00-1.05)

0.08

1.02 (1.00-1.05)

0.07

Serial sevens

1.00 (0.98-1.03)

0.87

1.01 (0.98-1.03)

0.68

Speed

Dual-Task Cost

Statistically significant values are bolded.
Abbreviations: MMSE = Mini Mental State Exam. HR = Hazard ratio.
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.
For gait speed, Hazard Ratio presented as 1/Exp(B).
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Table 4.9 Cox proportional hazard regression of the association of dichotomous gait
speed and dual-task cost with MMSE score decline
Model 1 (Unadjusted)
Variable

Model 2 (Adjusted)

HR (95% CI)

p-value

HR (95% CI)

p-value

Usual (<102.6cm/s)

1.32 (0.64-2.71)

0.45

1.12 (0.52-2.42)

0.76

Counting backwards
(<81.6cm/s)

1.06 (0.50-2.23)

0.87

1.08 (0.50-2.33)

0.84

Naming animals
(<75.1cm/s)

1.76 (0.84-3.72)

0.14

1.55 (0.72-3.33)

0.26

Serial sevens
(<60.7cm/s)

2.21 (0.91-5.39)

0.08

1.64 (0.65-4.18)

0.23

Counting Backwards
(>21.1%)

0.78 (0.36-1.69)

0.53

0.88 (0.40-1.95)

0.75

Naming animals
(>27.0%)

1.47 (0.71-3.05)

0.30

1.62 (0.77-3.40)

0.20

Serial sevens (>41.0%)

1.32 (0.58-3.00)

0.51

1.49 (0.64-3.44)

0.35

Speed

Dual-Task Cost

Statistically significant values are bolded.
Abbreviations: MMSE = Mini Mental State Exam. HR = Hazard ratio.
Model 1: unadjusted. Model 2: adjusted for age, sex and comorbidities.
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4.1.5

Data Attrition Measures

As only about a quarter of the original sample (n=107) was included in the longitudinal
analysis, it was also investigated why those who were not included did not have a second
visit within the study period. A summary of these findings is presented in Table 4.10.
The most common reasons for not being included in longitudinal analysis were related to
study criteria (n=134). One hundred and seventeen patients had a follow-up visit
scheduled, but it landed outside of the approved period of data collection, which ended in
June 2019. Sixteen patients had a second visit at the clinic that was less than twelve
months after their first. These were mostly consults and did not often include any new
testing. One patient was not able to be included in analysis as they were not able to
verbally communicate at the follow-up visit.
Thirty-four patients did not have any further follow-up scheduled in the Aging Brain and
Memory clinic. Thirty-two of these patients were referred to another service or
department for follow-up. Two of these patients were discharged at their baseline visit, as
they did not wish to be followed in the clinic.
Twenty-four patients were lost to follow-up. These included ten cancellations and twelve
patients who did not show-up for their appointments. Additionally, one patient
rescheduled their visit to after June 2019, making it no longer eligible, and one patient
moved out of the province.
No data was available for seventy-three patients at the time of data collection for followup visits.
Table 4.11 shows the comparison of baseline clinical and demographic characteristics
between those who were included in the longitudinal study (had a follow-up visit) and
those who weren’t. The two groups were statistically similar in all characteristics, except
MMSE score (p=0.008). However, the mean score for each of the two groups were less
than one point apart, so this is likely not a clinically significant difference.
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Table 4.10 Reasons for exclusion from longitudinal analysis for patients without a
second clinic visit
Reason for Exclusion

n

%

Lost to follow-up

24

6.5

Cancelled

10

2.7

No show

12

3.2

Rescheduled out of study period (after June 2019)

1

0.3

Moved out of province

1

0.3

34

9.1

Referred to another servicea

32

8.6

Discharged at baseline

2

0.5

134

36.0

Next visit after study end date (June 2019)

117

31.4

Next visit less than 12 months from baseline

16

4.3

Not able to complete cognitive testing at follow-upb

1

0.3

73

19.6

No follow-up scheduled

Study criteria

No data available
Percentage value is in comparison to total cohort.
Total cohort size n=372. Longitudinal analysis n=107.
a,

these included neuropsychology, long-term care, psychiatry, research, and other clinics

(due to geographic location).
b,

this patient had lost verbal communication skills.
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Table 4.11 Baseline demographic and clinical characteristics of study participants
stratified by inclusion in longitudinal study
Variable

Included (had
follow-up visit)
(n=107)

Not included (no
follow-up visit)
(n=265)

p-value

Age (mean, SD)

73.11 (9.47)

72.81 (10.32)

0.18

Female (n, %)

57 (53.3%)

132 (49.8%)

0.58

12.80 (3.01)a

12.59 (3.60)b

0.18

No. of Comorbidities
(mean, SD)

5.94 (2.99)

5.49 (3.34)

0.93

No. of medications (mean,
SD)

8.28 (3.86)

8.58 (3.40)

0.54

MMSE score (mean, SD)

25.76 (4.02)

25.12 (4.88)c

0.008

MoCA score (mean, SD)

20.76 (5.18)d

21.31 (4.98)e

0.74

SCI

19 (17.8%)

62 (23.4%)

0.30

MCI

51 (47.6%)

104 (39.2%)

Dementia

37 (34.6%)

99 (37.4%)

Years of education (mean,
SD)

Baseline diagnosis (n, %)

Statistically significant values are bolded.
Abbreviations: SCI = Subjective Cognitive Impairment. MCI = Mild Cognitive Impairment.
MMSE = Mini-Mental State Examination. MoCA = Montreal Cognitive Assessment.
a,

data available for n=99.

b,

data available for n=233.

c,

data available for n=263.

d,

data available for n=103.

e,

data available for n=236.

65

Chapter 5

5

General Discussion and Conclusions

5.1

Discussion

This thesis aimed to assess dual-task gait performance in a memory clinic setting across
the spectrum of cognitive impairment diagnoses. It was hypothesized that slow gait speed
and high dual-task cost would be associated with a more severe baseline cognitive
diagnosis, and would be associated with accelerated cognitive decline at a follow-up visit.
Our results showed that slow usual gait speed and slow gait speed while dual-tasking was
associated with a diagnosis of dementia at baseline. Also, dual-task gait testing was able
to be completed with almost 88% of eligible participants over a four year period,
demonstrating that gait testing is feasible to perform in clinics. In our longitudinal
analysis, there was a signal that poor dual-task gait performance at baseline, specifically
in the naming animals task, may be associated with cognitive decline at the follow-up
visit.

5.1.1

Cross-Sectional Gait Performance

Our results show that gait speed decreases across the spectrum of cognitive impairments,
confirming in a clinical setting the relationship between gait and cognition that has been
seen is other studies [132]. Gait speed was significantly different both across diagnosis
groups and between different dual-tasks with each group. Interestingly, in all four dualtask conditions the SCI and MCI groups had statically similar performance. This means
the SCI group had normal scores on tests of global cognition [133,134], but performed
similar in the dual-task test to the MCI group, who have objective cognitive impairments.
As we know patients with SCI are at increased risk for future cognitive decline [41], it is
possible the dual-task test is able to detect these early subtle changes in cognition that
cannot yet be seen on global cognitive testing. For example, the level of stress put on the
brain as a result of the dual-task gait test may be more than or target different resources
than traditional cognitive tests, and is therefore able to detect deficits at even the earliest
stage. Further studies using a healthy control group with no cognitive complaints and a
longer follow-up period would be needed to confirm this theory.
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All groups had a mean usual gait speed of over 80 cm/s, with the SCI group at 111 cm/s,
the MCI group at 106 cm/s, the dementia group at 91 cm/s, and 102cm/s as the mean for
the whole cohort. Eighty cm/s is considered to be the cut-off for slow gait speed in
association with gait pathologies and falls risk [70]. This means our sample had moderate
to high mobility function [88,117], and using this cut-off alone would not have been
sufficient to detect differences across the cognitive impairment groups. While mean gait
speed for the dementia group was still above 80 cm/s, the difference in mean gait speed
from the SCI and MCI groups was >10 cm/s, which is considered clinically meaningful
[135].
While the exact neural mechanisms behind the dual-task paradigm are not yet
understood, it is thought that both gait and cognitive tasks compete for a limited amount
of resources in overlapping brain regions. This is supported by imaging studies that have
shown higher activation in prefrontal brain regions when imagining walking while
talking versus just walking [105]. Alternatively, damage or atrophy in these shared brain
areas also causes detriments in both gait and cognition [103,104,136,137]. Our results are
in line with this theory, as those with more severe cognitive diagnoses had slower gait
speed, both in usual gait speed and while dual-tasking. Future neuroimaging studies
would be needed to expand on this theory.
Interestingly, dual-task gait cost was not significantly different between the diagnosis
groups. This goes against our original hypothesis and several other studies [96,132,138].
However, in the counting backwards and naming animals tasks, dual-task gait cost did
increase slightly across the groups as we hypothesized, although when using all four gait
tests together and excluding missing data this was not significant due to a power issue.
Due to our statistical analysis design and the clinical nature of our study, we had to
exclude a large number of participants from this analysis as they refused one or more of
the dual-task conditions. It is possible that those who refused one of the tasks had a
higher level of cognitive impairment and were embarrassed or fearful of attempting the
task. This would lead to the mean DTC in these groups being lower than it truly would be
if all participants had attempted the task. DTC did increase within each diagnosis group
with increasing task difficulty, as has been shown in previous studies [118].
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Regression analysis showed that slow gait speed and high dual-task cost were
significantly associated with diagnosis of dementia. Receiver operating characteristic
(ROC) curve analysis also showed that gait speed on each of the four gait tasks was low
to moderate, with area under the curve (AUC) ranging from .657 to .711. Sensitivity and
specificity for dementia diagnosis were also moderate, ranging from 62.8%-72.3% and
60.0%-64.9%, respectively. In comparison, the gold standard tests for cognitive
impairment, the MoCA and MMSE, were found to have sensitivity of 83% and 72% and
specificity of 86% and 83%, respectively, for predicting dementia [139]. While dual-task
gait testing is not as strong as these tests alone, it can be used in conjunction with these
traditional assessments as a quick and easy measure of the cognitive-motor interaction,
which these tests cannot measure, and to improve diagnosis and treatment plans for
patients. For example, a high dual-task gait cost may inform clinicians to send a patient
for more in depth neuropsychological evaluation or for brain imaging, which may catch
deficits at an earlier stage or give insight to the cause of these deficits.
Finally, our study has shown that dual-task gait testing is feasible to perform in a clinical
setting. Eighty-eight percent of eligible patients completed at least part of the gait testing
and could be included in analysis. A recent study of gait testing in an outpatient
neurology clinic had a similar rate of test completion (81%) [140]. This, in addition to
other studies done in a memory clinic setting [95,96], shows that dual-task gait testing
can be done even in busy clinic settings. Both assessors reported the testing was “pretty
easy” to complete and to add into the clinic visit. Some important tips for integration
were presented, including the use of a standard collection form and the requirement of
physical space. The methodology used here is quick, cost-effective, and requires minimal
equipment to be completed. While our results have shown some differences in sensitivity
and specificity between the different dual-tasks, it is still recommended to complete all
three tests. Even in a busy clinical setting, it usually takes under five minutes to complete
all four walks together, and it has been shown that the different cognitive tasks are
needed as they assess different domains of cognition and may together create the optimal
level of difficulty for all patients [141].
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5.1.2

Longitudinal Gait Performance

While the previous sub-study answered our research questions regarding feasibility and
practicality of gait testing and differences between diagnosis groups, there was still a gap
in the literature of a longitudinal study of gait testing across the cognitive spectrum in a
memory clinic cohort. Therefore, we decided to perform longitudinal analysis for any
participants who had a second clinic visit during the study period. It was hypothesized
that slow gait speed and greater dual-task gait cost at baseline would be predictive of
cognitive decline at the follow-up visit. Previous research has shown that dual-task gait
cost was a predictor of progression from MCI to dementia [15], however the limited
studies of dual-task gait testing in a clinical setting have not shown the same results [96].
Our results show a signal that dual-task performance in the naming animals condition
may be associated with change in diagnosis, which was a composite outcome including
change from SCI to MCI, MCI to dementia, and early to late dementia. Both continuous
gait speed and dual-task cost were associated with diagnosis change, even when adjusted
for covariates. Dichotomous slow gait speed (using a median split) while naming animals
was also associated with decline in diagnosis, although this association was not robust to
adjustment for confounders. Several past studies have also found usual gait speed to have
a weaker association with cognitive status and future cognitive decline [15,132,142,143].
However, differential associations between the dual-task conditions has not been
thoroughly examined previously. It is possible that because the naming animals condition
relies more purely on recall and semantic memory [144], while the arithmetic tasks rely
on executive functions [145], that the naming animals task was most sensitive to changes
as clinic patients were often being assessed for memory complaints. Alternatively, it is
also possible that the naming animals task provides the optimal level of difficulty while
also keeping patients’ mental engagement (ie. not “giving up”). Naming animals is also a
more universal task for a wide range of patients, as it has less influence from education
level [146]. Additional cognitive testing to determine which cognitive domains are
impaired in our cohort would be needed to examine this further.
Additionally, the association between poor gait performance at baseline and decline on
cognitive testing was examined. It was found that again, the only condition to show a
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signal of association was the naming animals task. Continuous dual-task cost while
naming animals was significantly associated with decline of >2 points per year on the
Montreal Cognitive Assessment (MoCA). Continuous slow gait speed while naming
animals was associated with decline of >2 points per year on the Mini Mental State Exam
(MMSE). Both of these associations remained significant even when adjusted for
covariates. Similarly to the previous result, it is possible that the differential domains and
pathways used in these dual-tasks could explain why only the naming animals dual-task
shows a signal of association. Also, because the MoCA and MMSE are both measures of
global cognitive function and not any domain specifically, it is possible that cognitive
tests tailored to one specific cognitive domain would show a higher association with gait
performance, especially in subtypes of each cognitive diagnosis.
While only 28.8% of participants could be included in longitudinal analysis, only 6.5% of
participants were confirmed lost to follow-up. Thirty six percent of participants could not
be included as their second visit to the clinic fell outside of the time range of the study.
Nine percent (9.1%) of patients were not scheduled to be followed in the clinic for
reasons not related to the study, and 19.6% of patients were not able to be included in
follow-up analyses due to missing data. As the largest proportion of patients were
excluded due to time constraints, both directly by the study design and indirectly by the
scheduling constraints in a busy clinic, the study follow-up period should be extended in
future studies to better capture the entire study sample. Still, even if we assume all
patients who could not be included due inaccessible data were lost to follow-up, we only
had an annual dropout rate of 6.5% of patients, which is comparable to other large
observational memory clinic studies [147,148].

5.1.3

Strengths

This study is the largest investigation of dual-task gait testing in clinical patients to date,
and includes all three common diagnosis groups. This demonstrates the feasibility of
performing dual-task gait testing in a busy clinical setting, as a high percentage of total
patients completed the assessment. Also, this thesis presents both cross-sectional and
longitudinal analyses of gait and cognitive performance. Finally, we used previously
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published gait testing guidelines [14], which will make comparison of our data to other
large cohorts possible.

5.1.4

Limitations

Our analyses also have several limitations that we acknowledge. Firstly, using limited
exclusion criteria allowed us to sample a large majority of the clinic population, but could
lead to increased heterogeneity in each diagnosis group. Subtypes of MCI and dementia
were grouped together, which may have implications on the relationship between gait
performance and cognitive outcomes. For example, it has been shown in the past that
dual-task gait testing may better predict conversion to vascular dementia than
Alzheimer’s disease [149]. The associations found in this current study may be
influenced by strong associations within one subtype, even with weaker associations or
no association at all possible in other subtypes. Our statistical analysis design for crosssectional comparisons of gait speed and DTC required that any patients who did not
complete all three dual-task be excluded from analysis. This could affect external
validity, as participants who refused one or more tasks could actually have worse
cognitive or mobility impairments than could be represented in the presented data. If
those excluded had worse performance on the other remaining dual-tasks the mean dualtask cost in these tasks is actually under-estimated in this sample and between group
differences may actually be larger than estimated here within. Additionally, we focused
on dual-task gait cost only, but adding dual-task cognitive cost to our methodology would
have improved our understanding of the dual-task paradigm in this sample. Information
on education level of patients was collected but was not used as a covariate in analyses,
which may impact the associations shown as education has a protective role in cognitive
function and decline. Finally, our study was only completed at one hospital based clinic
site in London, Ontario with a supervising team of one physician and one nurse clinician,
which may limit it’s generalizability to other clinic.

5.1.5

Future Directions

While our results fill in some of the current gaps in this area of literature, there are many
other research questions that still need to be addressed. Firstly, while we explored
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feasibility, sensitivity, and specificity of dual-task gait testing, it still needs to be
determined how this test could be useful in clinical practice and how it would fit with the
current gold standards of assessment. With the new results from this thesis, we have
shown that dual-task gait testing is associated with cognitive impairments in a clinical
setting, but how this could aid in differential diagnosis and treatment plans is still unclear.
Previously, we have published instructions to easily perform gait testing in clinics and
created videos to aid in the training of clinicians in this form of testing (see Appendix D).
This will assist greatly to facilitate the dissemination of this testing to additional clinic
sites and to allow the use of this testing to be further studied in other clinical settings.
Our results have shown a signal that dual-task performance at baseline may be associated
with future cognitive outcomes. However, larger studies with more homogenous samples
would be needed to further explore this relationship. For example, how this relationship
manifests in SCI to MCI, MCI to dementia, and early to late stage dementia transitions
should all be explored independently. They have unique factors that may influence the
how this association is expressed and how it can be applied in clinical diagnoses and
treatments.
Studies with a longer follow-up period may also show a stronger association between
baseline gait performance and cognitive decline. The follow-up period for our study
ranged from approximately one to three years. While some studies have found
meaningful changes in cognition in a similar time span [150], some studies report the
mean time needed to see clinically relevant symptoms may be more than twice as long as
this [151,152]. Therefore, the follow-up period of our study may have been too short to
capture the full picture of cognitive decline in our sample. Extending this follow-up
period in the future may show a stronger relationship between gait performance and
cognitive outcomes in a clinical setting.

5.2

Conclusions

This thesis has examined gait performance, specifically when dual-tasking, in a large
cohort of memory clinic patients, both cross-sectionally and longitudinally. Our result
show that gait speed and dual-task performance decline across the cognitive spectrum.
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Motor performance testing was feasible to perform in a real clinical scenario and results
were collected with minimal missing data. Additionally, we found a strong signal that
results from this testing can help to differentiate between cognitive diagnoses across the
spectrum of cognitive impairments seen in clinical settings. Our longitudinal analysis
showed that poor dual-task performance may be an indicator of risk of future cognitive
decline, however a larger sample with the opportunity to analyze each diagnosis group
separately would be needed to determine this.
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Appendix D: Byproducts of this Thesis and Links to Media
The following instructional video is included as a byproduct to this thesis. It outlines
instructions for how gait assessments are to be performed and recorded in a clinical
setting. This video was produced and edited by myself (Stephanie Cullen) and Manuel
Montero-Odasso with the help of the Gait and Brain Lab team.
Link: https://www.youtube.com/watch?v=DVAEENexaac&feature=emb_title

During my Masters, I also recreated our lab website with many online resources for
researchers and for patients who would like to learn more about gait testing and mobility.
These can be found at www.gaitandbrain.com.

More details about my research productivity and outputs during my Masters can be found
in my CV below.
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